Share this article
Share this article
RADNOR, Pa., April 26, 2021 /PRNewswire/ Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it will increase global capacity for high-quality single-use technologies used in the production of biologics and vaccines.
In the U.S. and Europe, the Company will increase its single-use manufacturing footprint by 30% and double its cleanroom space. The investment will support growing customer demand for monoclonal antibodies (mAbs), novel cell and gene therapies for oncology and other diseases, as well as vaccines, including those for COVID-19.